AroCell AB (publ) (AROC.ST) Research

AroCell AB (publ) is an in vitro diagnostics enterprise primarily focused on the surveillance of various cancerous conditions, such as hematological malignancies, breast cancer, and other solid tumors. The company develops, produces, and markets its flagship product, AroCell TK 210 ELISA, an immunoassay kit designed for measuring Thymidine Kinase 1 levels in human blood. Additionally, AroCell provides TUBEX TF, a rapid bacteriological test for the detection of typhoid fever. Founded in 2000, the firm was originally known as Xi Bao Research AB, adopting its current name, AroCell AB (publ), in 2006. It maintains its headquarters in Uppsala, Sweden.

Market snapshot

Symbol
AROC.ST
Price
$0.57
Day change
0.00%
Market cap
$103.7M
P/E ratio
41.67x
52-week range
0.346-0.66
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • AegirBio AB (publ) (AEGIR.ST)
  • CombiGene AB (publ) (COMBI.ST)
  • Dignitana AB (publ) (DIGN.ST)
  • Emplicure AB (publ) (EMPLI.ST)
  • FRISQ Holding AB (publ) (FRISQ.ST)
  • IRRAS AB (publ) (IRRAS.ST)
  • ISR Immune System Regulation Holding AB (publ) (ISR.ST)
  • Lipidor AB (publ) (LIPI.ST)

Open AroCell AB (publ) (AROC.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.